BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zachou K, Muratori P, Koukoulis GK, Granito A, Gatselis N, Fabbri A, Dalekos GN, Muratori L. Review article: autoimmune hepatitis -- current management and challenges. Aliment Pharmacol Ther. 2013;38:887-913. [PMID: 24010812 DOI: 10.1111/apt.12470] [Cited by in Crossref: 99] [Cited by in F6Publishing: 88] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang G, Tanaka A, Zhao H, Jia J, Ma X, Harada K, Wang FS, Wei L, Wang Q, Sun Y, Hong Y, Rao H, Efe C, Lau G, Payawal D, Gani R, Lindor K, Jafri W, Omata M, Sarin SK. The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatol Int 2021;15:223-57. [PMID: 33942203 DOI: 10.1007/s12072-021-10170-1] [Reference Citation Analysis]
2 Miyake Y, Yamamoto K, Matsushita H, Abe M, Takahashi A, Umemura T, Tanaka A, Nakamuta M, Nakamoto Y, Ueno Y, Saibara T, Takikawa H, Yoshizawa K, Ohira H, Zeniya M, Onji M, Tsubouchi H; Intractable Hepato-Biliary Disease Study Group of Japan. Multicenter validation study of anti-programmed cell death-1 antibody as a serological marker for type 1 autoimmune hepatitis: Serum anti-PD-1 antibody and type 1 AIH. Hepatol Res 2014;44:1299-307. [DOI: 10.1111/hepr.12305] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
3 Woynarowski M, Woźniak M, Cukrowska B, Wierzbicka A, Lytton SD. Autoantibody Profile of Adult Patients With Childhood Onset Type 2 Autoimmune Hepatitis. J Clin Lab Anal 2016;30:590-6. [PMID: 26676069 DOI: 10.1002/jcla.21907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Chen J, Liu W, Zhu W. Foxp3⁺ Treg Cells Are Associated with Pathological Process of Autoimmune Hepatitis by Activating Methylation Modification in Autoimmune Hepatitis Patients. Med Sci Monit 2019;25:6204-12. [PMID: 31422415 DOI: 10.12659/MSM.915408] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
5 Buechter M, Manka P, Heinemann FM, Lindemann M, Baba HA, Schlattjan M, Canbay A, Gerken G, Kahraman A. Potential triggering factors of acute liver failure as a first manifestation of autoimmune hepatitis-a single center experience of 52 adult patients. World J Gastroenterol 2018; 24(13): 1410-1418 [PMID: 29632422 DOI: 10.3748/wjg.v24.i13.1410] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
6 Gatselis NK, Vakrakou AG, Zachou K, Androutsakos T, Azariadis K, Hatzis G, Manoussakis MN, Dalekos GN. Decreased serum DNase1-activity in patients with autoimmune liver diseases. Autoimmunity 2017;50:125-32. [DOI: 10.1080/08916934.2017.1279610] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
7 Capra AP, Chiara E, Briuglia S. Autoimmune hepatitis in genetic syndromes: A literature review. World J Hepatol 2021; 13(10): 1328-1340 [PMID: 34786169 DOI: 10.4254/wjh.v13.i10.1328] [Reference Citation Analysis]
8 Grønbaek L, Vilstrup H, Jepsen P. Pregnancy and birth outcomes in a Danish nationwide cohort of women with autoimmune hepatitis and matched population controls. Aliment Pharmacol Ther 2018;48:655-63. [DOI: 10.1111/apt.14925] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
9 Muratori P, Carbone M, Stangos G, Perini L, Lalanne C, Ronca V, Cazzagon N, Bianchi G, Lenzi M, Floreani A, Invernizzi P, Muratori L. Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study. Dig Liver Dis 2018;50:698-702. [PMID: 29567415 DOI: 10.1016/j.dld.2018.02.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
10 Li YN, Ma H, Zhou L, Zhang J, Guo LP, Li SQ, Qian YQ, Wang BM. Autoimmune Hepatitis-related Cirrhosis: Clinical Features and Effectiveness of Immunosuppressive Treatment in Chinese Patients. Chin Med J (Engl) 2016;129:2434-40. [PMID: 27748335 DOI: 10.4103/0366-6999.191760] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Wang Z, Sheng L, Yang Y, Yang F, Xiao X, Hua J, Guo C, Wei Y, Tang R, Miao Q, Zhang J, Li Y, Fang J, Qiu D, Krawitt EL, Bowlus CL, Gershwin ME, Wang Q, Ma X. The Management of Autoimmune Hepatitis Patients with Decompensated Cirrhosis: Real-World Experience and a Comprehensive Review. Clinic Rev Allerg Immunol 2017;52:424-35. [DOI: 10.1007/s12016-016-8583-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
12 Zachou K, Weiler‐normann C, Muratori L, Muratori P, Lohse AW, Dalekos GN. Permanent immunosuppression in SLA/LP‐positive autoimmune hepatitis is required although overall response and survival are similar. Liver Int 2020;40:368-76. [DOI: 10.1111/liv.14280] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
13 Aizawa Y, Abe H, Sugita T, Seki N, Chuganji Y, Furumoto Y, Sakata A. Centrilobular zonal necrosis as a hallmark of a distinctive subtype of autoimmune hepatitis. Eur J Gastroenterol Hepatol 2016;28:391-7. [PMID: 26657454 DOI: 10.1097/MEG.0000000000000545] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
14 Zachou K, Gatselis NK, Arvaniti P, Gabeta S, Rigopoulou EI, Koukoulis GK, Dalekos GN. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. Aliment Pharmacol Ther. 2016;43:1035-1047. [PMID: 26991238 DOI: 10.1111/apt.13584] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 9.3] [Reference Citation Analysis]
15 Xia HH. Liver Diseases and Autoimmunity. J Clin Transl Hepatol 2013;1:144. [PMID: 26357612 DOI: 10.14218/JCTH.2013.00026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Xiao R, Chen N, Fang WL, Zhou L, Zhang J, Li S, Zheng ZQ, Wang BM, Liu WT. Abnormal peripheral blood lymphocyte subsets in patients with autoimmune hepatitis. Shijie Huaren Xiaohua Zazhi 2013; 21(35): 4006-4013 [DOI: 10.11569/wcjd.v21.i35.4006] [Reference Citation Analysis]
17 Rocco A, Sgamato C, Compare D, Nardone G. Autoimmune hepatitis following SARS-CoV-2 vaccine: May not be a casuality. J Hepatol 2021;75:728-9. [PMID: 34116081 DOI: 10.1016/j.jhep.2021.05.038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
18 Than NN, Ching DK, Hodson J, McDowell P, Mann J, Gupta R, Salazar E, Ngu JH, Oo YH. Difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between United Kingdom and Singapore patients. Hepatol Int 2016;10:673-9. [PMID: 27101826 DOI: 10.1007/s12072-016-9727-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
19 Dalekos GN, Azariadis K, Lygoura V, Arvaniti P, Gampeta S, Gatselis NK. Autoimmune hepatitis in patients aged 70 years or older: Disease characteristics, treatment response and outcome. Liver Int 2021;41:1592-9. [PMID: 33896089 DOI: 10.1111/liv.14900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Domerecka W, Kowalska-Kępczyńska A, Michalak A, Homa-Mlak I, Mlak R, Cichoż-Lach H, Małecka-Massalska T. Etiopathogenesis and Diagnostic Strategies in Autoimmune Hepatitis. Diagnostics (Basel) 2021;11:1418. [PMID: 34441353 DOI: 10.3390/diagnostics11081418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Granito A, Muratori P, Muratori L. Editorial: gut microbiota profile in patients with autoimmune hepatitis-a clue for adjunctive probiotic therapy? Aliment Pharmacol Ther 2020;52:392-4. [DOI: 10.1111/apt.15795] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
22 . EASL Clinical Practice Guidelines: Autoimmune hepatitis. Journal of Hepatology 2015;63:971-1004. [DOI: 10.1016/j.jhep.2015.06.030] [Cited by in Crossref: 489] [Cited by in F6Publishing: 395] [Article Influence: 69.9] [Reference Citation Analysis]
23 Gatselis NK, Zachou K, Lygoura V, Azariadis K, Arvaniti P, Spyrou E, Papadamou G, Koukoulis GK, Dalekos GN, Rigopoulou EI. Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece. Eur J Intern Med 2017;42:81-8. [PMID: 28535947 DOI: 10.1016/j.ejim.2017.05.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
24 Polychronopoulou E, Lygoura V, Gatselis NK, Dalekos GN. Increased cholestatic enzymes in two patients with long-term history of ulcerative colitis: consider primary biliary cholangitis not always primary sclerosing cholangitis. BMJ Case Rep. 2017;2017. [PMID: 28951510 DOI: 10.1136/bcr-2017-220824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Sandler YG, Saliev KG, Backih SN, Khomeriki SG, Khaymenova TY, Dorofeev AS, Sbikina ES, Vinnitskaya EV. [Сlinical, immunological and morphological features in different types of autoimmune hepatitis]. Ter Arkh 2020;92:43-7. [PMID: 32598717 DOI: 10.26442/00403660.2020.02.000536] [Reference Citation Analysis]
26 Caballero-Mateos AM, López Garrido MÁ, Becerra Massare P, de Teresa Galván J. Autoimmune severe acute fulminant hepatic failure (FHF) during pregnancy. Gastroenterol Hepatol 2018;41:259-60. [PMID: 28579277 DOI: 10.1016/j.gastrohep.2017.04.001] [Reference Citation Analysis]
27 Abdel-Razik A, Mousa N, Zakaria S, Elhelaly R, Elzehery R, Zalata K, Awad M, Eldeeb AA, Abdelsalam M. New predictive factors of poor response to therapy in autoimmune hepatitis: role of mean platelet volume. Eur J Gastroenterol Hepatol 2017;29:1373-9. [PMID: 29035910 DOI: 10.1097/MEG.0000000000000982] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
28 Rigopoulou EI, Gyftaki S, Arvaniti P, Tsimourtou V, Koukoulis GK, Hadjigeorgiou G, Dalekos GN. Autoimmune hepatitis in patients with multiple sclerosis: The role of immunomodulatory treatment. Clin Res Hepatol Gastroenterol 2019;43:e25-32. [PMID: 30594597 DOI: 10.1016/j.clinre.2018.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Azariadis K, Gatselis NK, Koukoulis GK, Dalekos GN. Glycogenic hepatopathy as a cause of severe deranged liver enzymes in a young patient with type 1 diabetes mellitus. BMJ Case Rep 2019;12:e228524. [PMID: 30898943 DOI: 10.1136/bcr-2018-228524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Than NN, Hodson J, Schmidt-Martin D, Taubert R, Wawman RE, Botter M, Gautam N, Bock K, Jones R, Appanna GD, Godkin A, Montano-Loza AJ, Lammert F, Schramm C, Manns MP, Swain M, Burak KW, Adams DH, Hirschfield GM, Oo YH. Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group. JHEP Rep 2019;1:437-45. [PMID: 32039395 DOI: 10.1016/j.jhepr.2019.10.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
31 Xia G, Wu S, Wang X, Fu M. Inhibition of microRNA-155 attenuates concanavalin-A-induced autoimmune hepatitis by regulating Treg/Th17 cell differentiation. Can J Physiol Pharmacol 2018;96:1293-300. [DOI: 10.1139/cjpp-2018-0467] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
32 Rigopoulou EI, Zachou K, Gatselis NK, Papadamou G, Koukoulis GK, Dalekos GN. Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome. World J Hepatol 2013; 5(10): 577-583 [PMID: 24179617 DOI: 10.4254/wjh.v5.i10.577] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
33 Hammerich L, Warzecha KT, Stefkova M, Bartneck M, Ohl K, Gassler N, Luedde T, Trautwein C, Tenbrock K, Tacke F. Cyclic adenosine monophosphate-responsive element modulator alpha overexpression impairs function of hepatic myeloid-derived suppressor cells and aggravates immune-mediated hepatitis in mice. Hepatology 2015;61:990-1002. [PMID: 25330465 DOI: 10.1002/hep.27571] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
34 Muratori P, Lalanne C, Bianchi G, Lenzi M, Muratori L. Predictive factors of poor response to therapy in Autoimmune Hepatitis. Digestive and Liver Disease 2016;48:1078-81. [DOI: 10.1016/j.dld.2016.06.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
35 Covelli C, Sacchi D, Sarcognato S, Cazzagon N, Grillo F, Baciorri F, Fanni D, Cacciatore M, Maffeis V, Guido M. Pathology of autoimmune hepatitis. Pathologica 2021;113:185-93. [PMID: 34294936 DOI: 10.32074/1591-951X-241] [Reference Citation Analysis]
36 Elkabbany ZA, Elbarbary NS, Ismail EA, Mohamed NA, Ragab D, Abdel Alem S, Ezzat YM, Maurice SS, Hashem NU. Transient elastography as a noninvasive assessment tool for hepatopathies of different etiology in pediatric type 1 diabetes mellitus. J Diabetes Complications 2017;31:186-94. [PMID: 27742550 DOI: 10.1016/j.jdiacomp.2016.09.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
37 Si CY, Xu Y, Bao J. Efficacy of α-glycyrrhizic acid in management of early autoimmune hepatitis. Shijie Huaren Xiaohua Zazhi 2014; 22(4): 568-572 [DOI: 10.11569/wcjd.v22.i4.568] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Dong Y, Potthoff A, Klinger C, Barreiros AP, Pietrawski D, Dietrich CF. Ultrasound findings in autoimmune hepatitis. World J Gastroenterol 2018; 24(15): 1583-1590 [PMID: 29686465 DOI: 10.3748/wjg.v24.i15.1583] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
39 Sener AG. Autoantibodies in autoimmune liver diseases. APMIS 2015;123:915-9. [DOI: 10.1111/apm.12442] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
40 Gatselis NK, Zachou K, Koukoulis GK, Dalekos GN. Autoimmune hepatitis, one disease with many faces: Etiopathogenetic, clinico-laboratory and histological characteristics. World J Gastroenterol 2015; 21(1): 60-83 [PMID: 25574080 DOI: 10.3748/wjg.v21.i1.60] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 66] [Article Influence: 10.4] [Reference Citation Analysis]
41 Gatselis NK, Dalekos GN. Molecular diagnostic testing for primary biliary cholangitis. Expert Review of Molecular Diagnostics 2016;16:1001-10. [DOI: 10.1080/14737159.2016.1217159] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
42 Peña-Vélez R, Almanza-Miranda E. [Autoimmune hepatitis in the pediatric age]. Bol Med Hosp Infant Mex 2017;74:324-33. [PMID: 29382475 DOI: 10.1016/j.bmhimx.2017.05.004] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
43 Minghui Z, Kunhua H, Yunwen B, Hongmei L, Jing L, Shaowen W, Longqiaozi S, Chaohui D. Analysis of Differentially Expressed Proteins Involved in Autoimmune Cirrhosis and Normal Serum by iTRAQ Proteomics. Proteomics Clin Appl 2019;13:e1700153. [PMID: 29999587 DOI: 10.1002/prca.201700153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
44 Hayat Davoudi G, Makvandi M, Teimoori A, Samarbafzade A, Biparva Haghighi S, Bavi A, Alavinejad P, Keyvani H. Frequency of OBI among Patients with Autoimmune Hepatitis. Asian Pac J Cancer Prev 2020;21:2555-9. [PMID: 32986352 DOI: 10.31557/APJCP.2020.21.9.2555] [Reference Citation Analysis]
45 Zachou K, Gampeta S, Gatselis NK, Oikonomou K, Goulis J, Manoussakis MN, Renaudineau Y, Bogdanos DP, Dalekos GN. Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis. Liver Int 2015;35:660-72. [DOI: 10.1111/liv.12658] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
46 Brissos J, Carrusca C, Correia M, Cabral J. Autoimmune hepatitis: trust in transaminases. BMJ Case Rep. 2014;2014. [PMID: 24759606 DOI: 10.1136/bcr-2014-203869] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
47 Dalekos GN, Gatselis NK. Variant and Specific Forms of Autoimmune Cholestatic Liver Diseases. Arch Immunol Ther Exp (Warsz) 2019;67:197-211. [PMID: 31165900 DOI: 10.1007/s00005-019-00550-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
48 Elfert KA, Qasim HM, Faisal MM, Elghazali A, Siddiqui MYA, Petkar M, Sadik N. Hepatitis E Viral Association with Autoimmune Hepatitis: A Viral Trigger or Cross-Reactivity. Case Rep Gastroenterol 2021;15:115-22. [PMID: 33708058 DOI: 10.1159/000509494] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Zachou K, Arvaniti P, Lyberopoulou A, Dalekos GN. Impact of genetic and environmental factors on autoimmune hepatitis. J Transl Autoimmun 2021;4:100125. [PMID: 34622188 DOI: 10.1016/j.jtauto.2021.100125] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Muratori P, Lalanne C, Barbato E, Fabbri A, Cassani F, Lenzi M, Muratori L. Features and Progression of Asymptomatic Autoimmune Hepatitis in Italy. Clin Gastroenterol Hepatol. 2016;14:139-146. [PMID: 26192146 DOI: 10.1016/j.cgh.2015.07.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
51 Muratori P, Efe C, Muratori L, Ozaslan E, Schiano T, Yoshida EM, Heurgué-berlot A, Lalanne C, Lenzi M, Wahlin S. Clinical implications of antimitochondrial antibody seropositivity in autoimmune hepatitis: a multicentre study. European Journal of Gastroenterology & Hepatology 2017;29:777-80. [DOI: 10.1097/meg.0000000000000870] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
52 Nares-cisneros J, Jaramillo-rodríguez Y. Hepatitis autoinmune en niños: evolución de 20 casos del norte de México. Revista de Gastroenterología de México 2014;79:238-43. [DOI: 10.1016/j.rgmx.2014.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
53 Dyson JK, Wong LL, Bigirumurame T, Hirschfield GM, Kendrick S, Oo YH, Lohse AW, Heneghan MA, Jones DEJ; UK-AIH Consortium. Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. Aliment Pharmacol Ther 2018;48:951-60. [PMID: 30226274 DOI: 10.1111/apt.14968] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
54 Narciso-Schiavon JL, Schiavon LL. Autoantibodies in chronic hepatitis C: A clinical perspective. World J Hepatol 2015; 7(8): 1074-1085 [PMID: 26052396 DOI: 10.4254/wjh.v7.i8.1074] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
55 Kimura N, Yamagiwa S, Sugano T, Horigome R, Setsu T, Tominaga K, Kamimura H, Takamura M, Terai S. Usefulness of chemokine C-C receptor 7- /programmed cell death-1+ follicular helper T cell subset frequencies in the diagnosis of autoimmune hepatitis. Hepatol Res 2019;49:1026-33. [PMID: 31020718 DOI: 10.1111/hepr.13356] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
56 Ebadi M, Bhanji RA, Mazurak VC, Lytvyak E, Mason A, Czaja AJ, Montano-loza AJ. Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis. Aliment Pharmacol Ther 2019;49:173-82. [DOI: 10.1111/apt.15029] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
57 Al-Hussaini AA, Alzahrani MD, Alenizi AS, Suliman NM, Khan MA, Alharbi SA, Chentoufi AA. Autoimmune hepatitis related autoantibodies in children with type 1 diabetes. Diabetol Metab Syndr 2014;6:38. [PMID: 24636465 DOI: 10.1186/1758-5996-6-38] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
58 Khayeka-Wandabwa C, Ma X, Jia Y, Bureik M. Concomitant occurence of multiple autoantibodies against human cytochromes P450. Int Immunopharmacol 2021;100:108087. [PMID: 34464888 DOI: 10.1016/j.intimp.2021.108087] [Reference Citation Analysis]
59 Mühling T, Rohrbach H, Schepp W, Gundling F. Overlap of concurrent extrahepatic autoimmune diseases is associated with milder disease severity of newly diagnosed autoimmune hepatitis. Hepatobiliary Pancreat Dis Int 2021;20:21-7. [PMID: 32830050 DOI: 10.1016/j.hbpd.2020.06.019] [Reference Citation Analysis]
60 Muratori P, Fabbri A, Lalanne C, Lenzi M, Muratori L. Autoimmune liver disease and concomitant extrahepatic autoimmune disease: . European Journal of Gastroenterology & Hepatology 2015;27:1175-9. [DOI: 10.1097/meg.0000000000000424] [Cited by in Crossref: 36] [Cited by in F6Publishing: 12] [Article Influence: 5.1] [Reference Citation Analysis]
61 Wang JB, Pu SB, Sun Y, Li ZF, Niu M, Yan XZ, Zhao YL, Wang LF, Qin XM, Ma ZJ. Metabolomic Profiling of Autoimmune Hepatitis: The Diagnostic Utility of Nuclear Magnetic Resonance Spectroscopy. J Proteome Res. 2014; Jun 30. [Epub ahead of print]. [PMID: 24940827 DOI: 10.1021/pr500462f] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
62 Muratori P, Lalanne C, Fabbri A, Cassani F, Lenzi M, Muratori L. Type 1 and type 2 autoimmune hepatitis in adults share the same clinical phenotype. Aliment Pharmacol Ther 2015;41:1281-7. [DOI: 10.1111/apt.13210] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
63 Dalekos GN, Koskinas J, Papatheodoridis GV. Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis. Ann Gastroenterol 2019;32:1-23. [PMID: 30598587 DOI: 10.20524/aog.2018.0330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
64 Kim HS, El-Serag HB. The Epidemiology of Hepatocellular Carcinoma in the USA. Curr Gastroenterol Rep. 2019;21:17. [PMID: 30976932 DOI: 10.1007/s11894-019-0681-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 12.3] [Reference Citation Analysis]
65 Santiago P, Schwartz I, Tamariz L, Levy C. Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis. Aliment Pharmacol Ther. 2019;49:830-839. [PMID: 30761563 DOI: 10.1111/apt.15157] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
66 Baven-Pronk MAMC, Biewenga M, van Silfhout JJ, van den Berg AP, van Buuren HR, Verwer BJ, van Nieuwkerk CMJ, Bouma G, van Hoek B. Role of age in presentation, response to therapy and outcome of autoimmune hepatitis. Clin Transl Gastroenterol. 2018;9:165. [PMID: 29961755 DOI: 10.1038/s41424-018-0028-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
67 Chen H, Chen X, Wang G. Platelets: A review of their function and effects in liver diseases. Liver Research 2020;4:129-35. [DOI: 10.1016/j.livres.2020.08.002] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Than NN, Jeffery HC, Oo YH. Autoimmune Hepatitis: Progress from Global Immunosuppression to Personalised Regulatory T Cell Therapy. Can J Gastroenterol Hepatol 2016;2016:7181685. [PMID: 27446862 DOI: 10.1155/2016/7181685] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
69 Wang J, Ma Z, Niu M, Zhu Y, Liang Q, Zhao Y, Song J, Bai Z, Zhang Y, Zhang P. Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum. Front Med. 2015;9:457-467. [PMID: 26459430 DOI: 10.1007/s11684-015-0417-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 6.7] [Reference Citation Analysis]
70 Malik N, Venkatesh SK. Imaging of autoimmune hepatitis and overlap syndromes. Abdom Radiol (NY) 2017;42:19-27. [PMID: 27999888 DOI: 10.1007/s00261-016-1019-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
71 Grønbaek H, Kreutzfeldt M, Kazankov K, Jessen N, Sandahl T, Hamilton-dutoit S, Vilstrup H, J. Møller H. Single-centre experience of the macrophage activation marker soluble (s)CD163 - associations with disease activity and treatment response in patients with autoimmune hepatitis. Aliment Pharmacol Ther 2016;44:1062-70. [DOI: 10.1111/apt.13801] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
72 Kalafateli M, Triantos C, Tsamandas A, Dalekos GN. Spontaneous Cirrhosis Regression in an IFN-beta-induced AIH-like Syndrome Following Drug Withdrawal: Art of Facts or Artifacts? Eur J Case Rep Intern Med 2016;3:000396. [PMID: 30755872 DOI: 10.12890/2016_000396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Arvaniti P, Zachou K, Koukoulis GK, Dalekos GN. Postinfantile Giant Cell Hepatitis with Features of Acute Severe Autoimmune Hepatitis Probably Triggered by Diclofenac in a Patient with Primary Myelofibrosis. Case Reports Hepatol 2018;2018:9793868. [PMID: 29713554 DOI: 10.1155/2018/9793868] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
74 Dalekos GN, Gatselis NK, Zachou K, Koukoulis GK. NAFLD and autoimmune hepatitis: Do not judge a book by its cover. Eur J Intern Med 2020;75:1-9. [PMID: 32051092 DOI: 10.1016/j.ejim.2020.02.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
75 González IA, Hartley CP, Nalbantoglu I. Recurrent Autoimmune Hepatitis and De Novo Autoimmune Hepatitis in the Liver Allograft. Am J Clin Pathol 2021;155:435-45. [PMID: 33252121 DOI: 10.1093/ajcp/aqaa147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Dalekos GN, Gatselis NK, Koukoulis GK. Non-alcoholic steatohepatitis or autoimmune hepatitis? Sometimes a closer look under the surface is needed. BMJ Case Rep 2020;13:e238400. [PMID: 33370951 DOI: 10.1136/bcr-2020-238400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Liberal R, de Boer YS, Andrade RJ, Bouma G, Dalekos GN, Floreani A, Gleeson D, Hirschfield GM, Invernizzi P, Lenzi M, Lohse AW, Macedo G, Milkiewicz P, Terziroli B, van Hoek B, Vierling JM, Heneghan MA; International Autoimmune Hepatitis Group (IAIHG). Expert clinical management of autoimmune hepatitis in the real world. Aliment Pharmacol Ther. 2017;45:723-732. [PMID: 28004405 DOI: 10.1111/apt.13907] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 8.2] [Reference Citation Analysis]
78 Gatselis NK, Skendros P, Ritis K, Dalekos GN. Severe liver involvement in two patients with long-term history of fever: remember familial Mediterranean fever. BMJ Case Rep 2016;2016:bcr2016216941. [PMID: 27659912 DOI: 10.1136/bcr-2016-216941] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
79 Muratori P, Granito A, Lenzi M, Muratori L. Limitation of the simplified scoring system for the diagnosis of autoimmune Hepatitis with acute onset. Liver Int 2021;41:529-34. [PMID: 33389800 DOI: 10.1111/liv.14778] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
80 Zachou K, Arvaniti P, Azariadis K, Lygoura V, Gatselis NK, Lyberopoulou A, Koukoulis GK, Dalekos GN. Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis. Hepatol Res 2019;49:96-104. [PMID: 30248210 DOI: 10.1111/hepr.13252] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
81 Wang Q, Yang F, Miao Q, Krawitt EL, Gershwin ME, Ma X. The clinical phenotypes of autoimmune hepatitis: A comprehensive review. J Autoimmun. 2016;66:98-107. [PMID: 26614611 DOI: 10.1016/j.jaut.2015.10.006] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 7.9] [Reference Citation Analysis]
82 Czaja AJ. Review article: chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets. Aliment Pharmacol Ther 2014;40:261-79. [DOI: 10.1111/apt.12825] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
83 Gatselis NK, Azariadis K, Lyberopoulou A, Dalekos GN. Programmed cell death-1 rs11568821 and interleukin-28B rs12979860 polymorphisms in autoimmune hepatitis. J Transl Autoimmun 2021;4:100126. [PMID: 34632357 DOI: 10.1016/j.jtauto.2021.100126] [Reference Citation Analysis]
84 Tansel A, Katz LH, El-Serag HB, Thrift AP, Parepally M, Shakhatreh MH, Kanwal F. Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2017; 15: 1207-1217. e4. [PMID: 28215616 DOI: 10.1016/j.cgh.2017.02.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
85 Sasaki T, Suzuki Y, Ishida K, Kakisaka K, Abe H, Sugai T, Takikawa Y. Autoimmune hepatitis following influenza virus vaccination: Two case reports. Medicine (Baltimore). 2018;97:e11621. [PMID: 30045302 DOI: 10.1097/md.0000000000011621] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
86 Dalekos GN, Zachou K. Editorial: autoimmune hepatitis - identifying options for treatment. Authors' reply. Aliment Pharmacol Ther 2016;43:1237-8. [PMID: 27137726 DOI: 10.1111/apt.13626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
87 Muratori P, Lenzi M, Cassani F, Lalanne C, Muratori L. Diagnostic approach to autoimmune hepatitis. Expert Rev Clin Immunol 2017;13:769-79. [PMID: 28480763 DOI: 10.1080/1744666X.2017.1327355] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
88 Wang QX, Yan L, Ma X. Autoimmune Hepatitis in the Asia-Pacific Area. J Clin Transl Hepatol 2018;6:48-56. [PMID: 29577032 DOI: 10.14218/JCTH.2017.00032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
89 Granito A, Pascolini S, Ricci C, Ferronato M, Muratori L, Vasuri F, Franceschini T, Lenzi M, Muratori P. Decompensated Cirrhosis as Presentation of LKM1/LC1 Positive Type 2 Autoimmune Hepatitis in Adulthood. A Rare Clinical Entity of Difficult Management. Gastroenterology Insights 2021;12:67-75. [DOI: 10.3390/gastroent12010007] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
90 Mieli-vergani G, Vergani D, Baumann U, Czubkowski P, Debray D, Dezsofi A, Fischler B, Gupte G, Hierro L, Indolfi G, Jahnel J, Smets F, Verkade HJ, Hadžić N. Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement. Journal of Pediatric Gastroenterology & Nutrition 2018;66:345-60. [DOI: 10.1097/mpg.0000000000001801] [Cited by in Crossref: 100] [Cited by in F6Publishing: 24] [Article Influence: 25.0] [Reference Citation Analysis]
91 El‐serag HB. Epidemiology of Hepatocellular Carcinoma. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, editors. The Liver. Wiley; 2020. pp. 758-72. [DOI: 10.1002/9781119436812.ch59] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
92 Rigopoulou EI, Dalekos GN. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers (Basel) 2021;13:1023. [PMID: 33804480 DOI: 10.3390/cancers13051023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
93 Yu ZJ, Zhang LL, Huang TT, Zhu JS, He ZB. Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis. Eur J Gastroenterol Hepatol 2019;31:873-7. [PMID: 31150366 DOI: 10.1097/MEG.0000000000001367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Rigopoulou EI, Gatselis N, Arvaniti P, Koukoulis GK, Dalekos GN. Alcoholic liver disease and autoimmune hepatitis: Sometimes a closer look under the surface is needed. Eur J Intern Med 2021;85:86-91. [PMID: 33451888 DOI: 10.1016/j.ejim.2020.12.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
95 Anand L, Choudhury A, Bihari C, Sharma BC, Kumar M, Maiwall R, Siam Tan S, Shah SR, Hamid S, Butt AS, Jafri W, Chawla YK, Taneja S, Duseja A, Dhiman RK, Mahtab MA, Ghazinyan H, Duan Z, Chen Y, Shukla A, Hu J, Abbas Z, Treeprasertsuk S, Lesmana LA, Lesmana CR, Sollano JD, Carpio G, Sahu MK, Kumar G, Sarin SK; APASL ACLF (APASL ACLF Research Consortium) Working Party. Flare of Autoimmune Hepatitis Causing Acute on Chronic Liver Failure: Diagnosis and Response to Corticosteroid Therapy. Hepatology 2019;70:587-96. [PMID: 30113706 DOI: 10.1002/hep.30205] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 11.7] [Reference Citation Analysis]
96 Kaffe ET, Rigopoulou EI, Koukoulis GK, Dalekos GN, Moulas AN. Oxidative stress and antioxidant status in patients with autoimmune liver diseases. Redox Rep 2015;20:33-41. [PMID: 25117650 DOI: 10.1179/1351000214Y.0000000101] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
97 Vitale G, Gitto S, Campani C, Turco L, Baldan A, Marra F, Morelli MC. Biological therapies in patients with liver disease: are they really lifesavers? Expert Opin Biol Ther 2021;:1-18. [PMID: 34860629 DOI: 10.1080/14712598.2022.2013799] [Reference Citation Analysis]